Home / Business News (page 3)

Business News

After Phase 3 Failure, AbbVie Discontinues Rova-T Research and Development Program

NORTH CHICAGO, Ill., Aug. 29, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research based global biopharmaceutical company, today announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit at a pre-planned interim analysis for patients receiving Rova-T as compared with …

Read More »

US Court Backs Sanofi, Regeneron in Amgen Suit for Patents on PCSK9 Drug

PARIS and TARRYTOWN, NY – August 28, 2019 – Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen’s asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) …

Read More »

Celgene and Immatics Enter up to $1.6 Billion Cancer T-Cell Collaboration

Houston, Texas and Tuebingen, Germany, August 28, 2019 – Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Immatics and Celgene Corporation have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple …

Read More »

Adaptimmune and Noile-Immune Partner to Develop Next Generation Treatments for Cancer with T-Cell Technology

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Noile-Immune Biotech, Inc., Tokyo, Japan, a biotechnology company focusing on the development of innovative cancer immunotherapies, today announced that they will co-develop next-generation SPEAR T-cell products, …

Read More »

Mustang Bio Enters License Agreement with CSL Behring for the Cytegrity Stable Producer Cell Line for Production of MB-107 Lentiviral Gene Therapy

NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it has entered into a license …

Read More »

Kintai Therapeutics Announces Collaborations with Leading Academic Centers to Identify Novel Targets for Cancer

CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) — Kintai Therapeutics, a Flagship Pioneering company, today announced that it has established new collaborations with leading academic institutions to identify novel molecules that play a fundamental role in microbe to human communication in different forms of cancer. The company has started to …

Read More »

Zogenix to Acquire Modis Therapeutics for $250 Million, Strengthening its Rare Disease Pipeline

EMERYVILLE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) —  Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into a definitive agreement to acquire Modis Therapeutics, Inc., a privately held biopharmaceutical company focused on developing novel therapies for rare genetic diseases with …

Read More »

Amgen to Acquire Celgene’s Psoriasis Drug Otezla for $13.4 Billion in Cash

THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets …

Read More »

Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

FOSTER CITY, Calif. & MECHELEN, Belgium–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019. This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust …

Read More »

Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates

VIENNA–(BUSINESS WIRE)–Themis Bioscience announced today a research collaboration and exclusive license agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform. “Given the versatility of our immune-modulation platform and our proven ability to rapidly …

Read More »